Trading on analyst upgrades and downgrades is foolish.
I'm betting with the buyers here.
First they told investors to buy, now ignoring those investors, they say to sell. Why would anyone listen to these guys?
does this make any sense????
WBB Securities downgraded shares of Sarepta Therapeutic (SRPT) from a hold rating to a sell rating. Their analysts now have a $9.00 price target on the stock, up previously from $8.00
Sentiment: Strong Buy